Skip to main content

Table 5 Association between waiting time and the change in SF-12v2 mental component scale from baseline to the 6-month follow-up, for the overall sample and by main rheumatic condition

From: The association between waiting time and multidisciplinary pain treatment outcomes in patients with rheumatic conditions

  MCS at baseline, Mean (SD) MCS at 6 months, Mean (SD) GEE models
Unadj. p value a Unadj. change from baseline to 6 months, EMM (95% CI) Adj.
p value a,b
Adj. change from baseline to 6 months, EMM b (95% CI)
Overall sample (n) 3210 1940 0.000   0.001  
 Total 29.1 (11.4) 31.6 (12.5)     
 < 2 months 29.9 (11.7) 33.5 (13.0)   3.6 [2.4, 4.9]   3.7 [2.3, 5.0]
 2–6 months 28.7 (11.5) 30.5 (12.6)   1.4 [0.4, 2.4]   1.5 [0.3, 2.6]
 > 6 months 28.8 (11.0) 31.0 (11.8)   1.9 [1.0, 2.8]   2.0 [1.0, 3.0]
Osteoarthritis (n) 665 395 0.112   0.308  
 Total 31.4 (11.3) 33.5 (12.3)     
 < 2 months 30.7 (11.4) 33.7 (12.1)   3.4 [0.7, 6.2]   3.2 [0.3, 6.2]
 2–6 months 31.5 (11.9) 33.4 (13.3)   1.1 [−1.2, 3.4]   1.6 [−1.3, 4.4]
 > 6 months 32.0 (10.6) 33.5 (11.5)   1.2 [−0.9, 3.29]   1.5 [−0.8, 3.7]
Fibromyalgia (n) 670 358 0.021   0.012  
 Total 27.2 (11.0) 29.0 (12.6)     
 < 2 months 27.9 (10.5) 32.7 (12.2)   4.9 [1.7, 8.1]   4.9 [1.5, 8.3]
 2–6 months 27.7 (11.8) 28.9 (13.7)   1.6 [−0.6, 3.8]   0.9 [−1.1, 3.0]
 > 6 months 26.3 (10.5) 27.1 (11.4)   1.3 [−0.6, 3.21]   1.0 [−1.0, 2.9]
  1. MCS SF-12v2 Mental component scale, SD standard deviation, GEE generalized estimating equations, EMM estimated marginal means, 95% CI 95% confidence interval
  2. a Time X group effect p value
  3. b Adjusted for age, sex, pain duration, number of comorbidities and income